These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 14965296)

  • 41. Molecular similarity measures.
    Maggiora GM; Shanmugasundaram V
    Methods Mol Biol; 2011; 672():39-100. PubMed ID: 20838964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An overview of molecular fingerprint similarity search in virtual screening.
    Muegge I; Mukherjee P
    Expert Opin Drug Discov; 2016; 11(2):137-48. PubMed ID: 26558489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular optimization using computational multi-objective methods.
    Nicolaou CA; Brown N; Pattichis CS
    Curr Opin Drug Discov Devel; 2007 May; 10(3):316-24. PubMed ID: 17554858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Similarity Concepts for Informatics Applications.
    Bajorath J
    Methods Mol Biol; 2017; 1526():231-245. PubMed ID: 27896745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expanding the medicinally relevant chemical space with compound libraries.
    López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
    Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topological descriptors in drug design and modeling studies.
    Roy K
    Mol Divers; 2004; 8(4):321-3. PubMed ID: 15612635
    [No Abstract]   [Full Text] [Related]  

  • 48. Emerging chemical patterns: a new methodology for molecular classification and compound selection.
    Auer J; Bajorath J
    J Chem Inf Model; 2006; 46(6):2502-14. PubMed ID: 17125191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology.
    Kéri G; Székelyhidi Z; Bánhegyi P; Varga Z; Hegymegi-Barakonyi B; Szántai-Kis C; Hafenbradl D; Klebl B; Muller G; Ullrich A; Erös D; Horváth Z; Greff Z; Marosfalvi J; Pató J; Szabadkai I; Szilágyi I; Szegedi Z; Varga I; Wáczek F; Orfi L
    Assay Drug Dev Technol; 2005 Oct; 3(5):543-51. PubMed ID: 16305311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery.
    Koch MA; Waldmann H
    Drug Discov Today; 2005 Apr; 10(7):471-83. PubMed ID: 15809193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three decades of structure- and property-based molecular design.
    Müller K
    Chimia (Aarau); 2014; 68(7-8):472-82. PubMed ID: 25437386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemodiversity and molecular plasticity: recognition processes as explored by property spaces.
    Vistoli G; Pedretti A; Testa B
    Future Med Chem; 2011 Jun; 3(8):995-1010. PubMed ID: 21707401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Flexible 3D pharmacophores as descriptors of dynamic biological space.
    Nettles JH; Jenkins JL; Williams C; Clark AM; Bender A; Deng Z; Davies JW; Glick M
    J Mol Graph Model; 2007 Oct; 26(3):622-33. PubMed ID: 17395510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beyond mere diversity: tailoring combinatorial libraries for drug discovery.
    Martin EJ; Critchlow RE
    J Comb Chem; 1999 Jan; 1(1):32-45. PubMed ID: 10746013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design.
    Patel Y; Gillet VJ; Howe T; Pastor J; Oyarzabal J; Willett P
    J Med Chem; 2008 Dec; 51(23):7552-62. PubMed ID: 19012393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Automated medicinal chemistry.
    Koppitz M; Eis K
    Drug Discov Today; 2006 Jun; 11(11-12):561-8. PubMed ID: 16713909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective optimization of side activities: another way for drug discovery.
    Wermuth CG
    J Med Chem; 2004 Mar; 47(6):1303-14. PubMed ID: 14998318
    [No Abstract]   [Full Text] [Related]  

  • 59. [Strategy of molecular drug design: activity and druggability].
    Guo ZR
    Yao Xue Xue Bao; 2010 May; 45(5):539-47. PubMed ID: 20931752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leadlikeness and structural diversity of synthetic screening libraries.
    Verheij HJ
    Mol Divers; 2006 Aug; 10(3):377-88. PubMed ID: 17031539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.